V-AKT Antibody

Biochemical Characteristics of V-AKT Antibodies

V-AKT antibodies recognize isoforms of the AKT family (AKT1, AKT2, AKT3) and their phosphorylated forms. Key features include:

For example, Proteintech’s AKT antibody (10176-2-AP) detects a 56–62 kDa band in WB and shows reactivity across human, mouse, and rat tissues .

Cancer Biology

• Mechanistic Insights: AKT antibodies identify hyperactivation in cancers (e.g., ovarian, lung, pancreatic) via PI3K/AKT/mTOR pathway dysregulation .

• Therapeutic Targeting: Antibodies like MAB2055 (R&D Systems) validate AKT inhibition by drugs such as ipatasertib and capivasertib in clinical trials .

Immunology

• Lymphocyte Regulation: AKT1 dominates in B cells, influencing germinal center formation and antibody production .

• ɣδ T Cell Activation: Antibodies detect AKT’s role in IPP-mediated activation and cytotoxicity via PI3K/AKT/mTOR signaling .

AKT Inhibitor Development

These inhibitors reduce tumor growth by blocking AKT-mediated survival signals, validated using phosphorylation-specific antibodies .

Disease Associations

• Chronic Lymphocytic Leukemia (CLL): AKT antibodies confirm constitutive activation in CLL clones, linking to MCL1 stabilization and apoptosis resistance .

• Breast Cancer: Isoform-specific antibodies reveal AKT1 overexpression in HER2+ tumors, correlating with poor prognosis .

Technical Considerations for Antibody Use

• Buffer Compatibility: Requires 0.02 M potassium phosphate (pH 7.2) for stability; sodium azide-preserved .

• Cross-Reactivity: Some clones (e.g., ABIN94783) show variable affinity across species, necessitating validation .

• Phospho-Specificity: Harsh extraction methods (e.g., boiling in SDS) improve detection of active AKT in leukemic cells .

Emerging Insights

• Metabolic Regulation: AKT antibodies track glucose metabolism in cancer via GSK3β and mTORC1 signaling .

• Drug Resistance: Persistent AKT activation in tumors post-treatment is detectable via phospho-Ser473 antibodies, guiding combination therapies .